Form 4 for PLRX PLIANT THERAPEUTICS, INC.
Accepted 2022-09-14 00:00:00 ET · period of report 2022-09-12 · accession 0001567619-22-017430 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-14 | 2022-09-12 | PLRX | Coulie Bernard | Pres, CEO, Dir | S - Sale+OE | $22.54 | -12.5K | 59.3K | -17% | -$281.8K |
| D | 2022-09-14 | 2022-09-12 | PLRX | Coulie Bernard | Pres, CEO, Dir | M - OptEx | $2.08 | +12.5K | 71.8K | +21% | +$26.0K |
| D | 2022-09-14 | 2022-09-12 | PLRX | Coulie Bernard | Pres, CEO, Dir | M - OptEx | $0.00 | -12.5K | 297.4K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-12 | S | D | 12,502 | $22.54 | 59,273 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.69, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| 2 | Common | Common Stock | 2022-09-12 | M | A | 12,502 | $2.08 | 71,775 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2022-09-12 | M | D | 12,502 | $0.00 | 297,380 | D | $2.08 · — to 2029-01-23 | 12,502 Common Stock | (F4) 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. |